StockNews.com Upgrades LivaNova (NASDAQ:LIVN) to Strong-Buy

LivaNova (NASDAQ:LIVN) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Tuesday.

A number of other equities research analysts also recently issued reports on the stock. The Goldman Sachs Group started coverage on shares of LivaNova in a report on Friday, October 4th. They issued a “buy” rating and a $65.00 target price for the company. Robert W. Baird boosted their price objective on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Mizuho dropped their price objective on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 target price on shares of LivaNova in a report on Monday, November 25th. Finally, Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, LivaNova has an average rating of “Buy” and a consensus price target of $69.17.

LivaNova Price Performance

LIVN stock opened at $47.59 on Tuesday. The stock has a market capitalization of $2.58 billion, a price-to-earnings ratio of 113.31 and a beta of 0.98. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova has a 52-week low of $43.15 and a 52-week high of $64.47. The stock’s fifty day simple moving average is $51.79 and its 200-day simple moving average is $51.25.

Insider Buying and Selling at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the sale, the director now owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.27% of the stock is owned by corporate insiders.

Institutional Trading of LivaNova

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Point72 Asset Management L.P. lifted its holdings in LivaNova by 204.3% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company’s stock worth $70,479,000 after buying an additional 863,157 shares during the last quarter. First Light Asset Management LLC raised its position in shares of LivaNova by 591.1% during the 2nd quarter. First Light Asset Management LLC now owns 710,390 shares of the company’s stock valued at $38,944,000 after acquiring an additional 607,598 shares in the last quarter. Great Lakes Advisors LLC bought a new position in LivaNova during the second quarter worth $16,614,000. Driehaus Capital Management LLC boosted its holdings in LivaNova by 64.7% in the second quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock worth $29,824,000 after purchasing an additional 213,749 shares during the period. Finally, Point72 DIFC Ltd increased its stake in LivaNova by 75,799.6% during the third quarter. Point72 DIFC Ltd now owns 181,400 shares of the company’s stock valued at $9,531,000 after purchasing an additional 181,161 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.